Print DTC ads emphasizing the ability of Merck/Schering-Plough's Vytorin to reduce LDL-cholesterol levels began running on March 30. Following an FDA request in January, the ads carry the disclaimer that "Vytorin has not been shown to reduce heart attacks or strokes more than Zocor alone." A recent article mistakenly said the statement is being included in DTC ads as a result of safety signals identified in the ENHANCE trial (1"The Pink Sheet," April 14, 2008, In Brief). Furthermore, no new safety signals were associated with Vytorin treatment in the ENHANCE trial
You may also be interested in...
DTC print advertisements for Merck/Schering-Plough's Vytorin (ezetimibe/simvastatin) began carrying a bolded warning March 30 to highlight safety signals identified in the ENHANCE study. The print ad, "Do you have high LDL (bad) cholesterol," ran through April 6 and contained a statement that "Vytorin has not been shown to reduce heart attacks or strokes more than Zocor alone." The statement also will appear in broadcast ads for the drug, the firm tells "The Pink Sheet." The Vytorin buzz shares the DTC spotlight with Pfizer's ads for Lipitor, which gained attention for its celebrity endorsement by Robert Jarvick last month (1"The Pink Sheet," March 3, 2008, p. 10)
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.